Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.57%
#2 aelf aelf +21.73%
#3 Bitway Bitway +21.43%
#4 Pons Pons +14.64%
#5 Starpower Starpower +13.58%
#6 Decred Decred +13.13%
#7 TRIA TRIA +12.68%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +12.22%
#9 DAPPOS DAPPOS +9.61%
#10 Wibx Wibx +8.12%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

SYN
Pozycja w akcjach #30609
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on... Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the proliferation of harmful bacteria, combat antimicrobial resistance (AMR), and mitigate acute graft-versus-host-disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key asset is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, intended to address both localized gastrointestinal and systemic conditions. The company is also advancing VCN-01, a therapeutic candidate for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Additional clinical-stage programs include SYN-006, targeting the prevention of aGVHD and infections from carbapenem-resistant enterococci; SYN-007, designed to avert antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for the prevention and treatment of whooping cough (pertussis); and VCN-11, another cancer therapeutic. Synthetic Biologics maintains partnerships with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis supports a Phase 1b/2a clinical trial for SYN-004. The company's main operations are based in Rockville, Maryland.
Cena akcji
$1.02
Ostatnia synchronizacja: 2022-10-13
Kapitalizacja rynkowa
$16.16M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Synthetic Biologics, Inc. (SYN)

Kategoria

Healthcare
Historia ceny akcji dla Synthetic Biologics, Inc. (SYN)
Najwyższa cena zamknięcia: $1.05 dnia 2022-10-01

Najniższa cena zamknięcia: $838.79 dnia 2012-02-01
Historia cen akcji firmy Synthetic Biologics, Inc. od 2012 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2022 -66.74%
2021 -13.70%
2020 -18.74%
2019 -28.68%
2018 -96.72%
2017 -33.18%
2016 -66.52%
2015 62.87%
2014 20.10%
2013 -27.54%
2012 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $527.89 35.09%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $996.61 51.72%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $114.99 -21.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $735.86 6.07%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.06K -6.07%
KR